[go: up one dir, main page]

NO20090606L - Aminofosforsyreester derivat og S1P reseptor modulator inneholdende den samme som aktiv ingresiens - Google Patents

Aminofosforsyreester derivat og S1P reseptor modulator inneholdende den samme som aktiv ingresiens

Info

Publication number
NO20090606L
NO20090606L NO20090606A NO20090606A NO20090606L NO 20090606 L NO20090606 L NO 20090606L NO 20090606 A NO20090606 A NO 20090606A NO 20090606 A NO20090606 A NO 20090606A NO 20090606 L NO20090606 L NO 20090606L
Authority
NO
Norway
Prior art keywords
active ingredient
acid ester
same
ester derivative
receptor modulator
Prior art date
Application number
NO20090606A
Other languages
English (en)
Norwegian (no)
Inventor
Yasushi Kohno
Kiyoshi Fujii
Tatsuhiro Saito
Original Assignee
Kyorin Seiyaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Seiyaku Kk filed Critical Kyorin Seiyaku Kk
Publication of NO20090606L publication Critical patent/NO20090606L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
NO20090606A 2006-08-08 2009-02-10 Aminofosforsyreester derivat og S1P reseptor modulator inneholdende den samme som aktiv ingresiens NO20090606L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006215280 2006-08-08
PCT/JP2007/065397 WO2008018427A1 (fr) 2006-08-08 2007-08-07 Dérivé d'ester de l'acide aminophosphorique et modulateur du récepteur s1p contenant ledit dérivé en tant que principe actif

Publications (1)

Publication Number Publication Date
NO20090606L true NO20090606L (no) 2009-03-03

Family

ID=39032957

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090606A NO20090606L (no) 2006-08-08 2009-02-10 Aminofosforsyreester derivat og S1P reseptor modulator inneholdende den samme som aktiv ingresiens

Country Status (26)

Country Link
US (1) US8232319B2 (fr)
EP (1) EP2058317B1 (fr)
JP (1) JP5188972B2 (fr)
KR (1) KR101339976B1 (fr)
CN (1) CN101501049B (fr)
CA (1) CA2659598A1 (fr)
CY (1) CY1114681T1 (fr)
DK (1) DK2058317T3 (fr)
ES (1) ES2438265T3 (fr)
HR (1) HRP20131172T1 (fr)
IL (1) IL196275A (fr)
MA (1) MA30663B1 (fr)
ME (1) ME02095B (fr)
MX (1) MX2009001456A (fr)
MY (1) MY152176A (fr)
NO (1) NO20090606L (fr)
NZ (1) NZ574011A (fr)
PL (1) PL2058317T3 (fr)
PT (1) PT2058317E (fr)
RS (1) RS53080B (fr)
RU (1) RU2430925C2 (fr)
SG (1) SG174028A1 (fr)
SI (1) SI2058317T1 (fr)
TN (1) TNSN08545A1 (fr)
WO (1) WO2008018427A1 (fr)
ZA (1) ZA200900206B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
JPWO2009142194A1 (ja) * 2008-05-19 2011-09-29 杏林製薬株式会社 光学活性アミノアルコール誘導体の製造方法
JPWO2009142195A1 (ja) * 2008-05-20 2011-09-29 杏林製薬株式会社 寛解導入維持剤
US8580841B2 (en) 2008-07-23 2013-11-12 Arena Pharmaceuticals, Inc. Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
EP2342205B1 (fr) 2008-08-27 2016-04-20 Arena Pharmaceuticals, Inc. Derives d'acides tricycliques substitues, utiles dans le traitement des troubles auto-immuns et inflammatoires
HRP20141065T1 (hr) * 2009-07-09 2015-02-13 Kyorin Pharmaceutical Co., Ltd. Derivati difenil-sulfida i lijekovi koji ih sadrže kao aktivni sastojak
EP4148045A1 (fr) 2010-01-27 2023-03-15 Arena Pharmaceuticals, Inc. Composés intermédiaires pour la préparation de l'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclopenta[b]indol-3-yl) acétique et de ses sels
ES2558087T3 (es) 2010-03-03 2016-02-01 Arena Pharmaceuticals, Inc. Procesos para la preparación de moduladores del receptor S1P1 y formas cristalinas de los mismos
TWI519539B (zh) 2010-12-21 2016-02-01 Kyorin Seiyaku Kk Diphenyl sulfide derivatives and pharmaceuticals as an active ingredient thereof
US8513418B2 (en) * 2011-04-18 2013-08-20 Allergan, Inc. Substituted bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators
CN102863345A (zh) * 2011-07-06 2013-01-09 中国医学科学院药物研究所 胺基丙二醇类衍生物、其制备方法和其药物组合物与用途
WO2015194157A1 (fr) * 2014-06-16 2015-12-23 杏林製薬株式会社 Procédé de fabrication et intermédiaire de fabrication de dérivé diphénylsulfure
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
CA3002551A1 (fr) 2015-06-22 2016-12-29 Arena Pharmaceuticals, Inc. Sel cristallin de l-arginine de (r)(7-(4-cyclopentyle-3-(trifluoromethyle)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acide acetique(compose 1) aux fins d'utilisation contre les troubles associes au recepteur s1p1
CN109314445B (zh) 2016-06-07 2021-04-27 特斯拉公司 电动机转子放电保护
CA3053418A1 (fr) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Composes et methodes de traitement de l'angiocholite biliaire primitive
WO2018151834A1 (fr) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Composés et méthodes pour le traitement de maladies inflammatoires chroniques de l'intestin avec manifestations extra-intestinales
US10967702B2 (en) 2017-09-07 2021-04-06 Tesla, Inc. Optimal source electric vehicle heat pump with extreme temperature heating capability and efficient thermal preconditioning
CA3102136A1 (fr) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methodes de traitement de troubles associes au recepteur s1p1<sb />
CN119751336A (zh) 2018-09-06 2025-04-04 艾尼纳制药公司 可用于治疗自身免疫性病症和炎性病症的化合物
KR20210133984A (ko) 2019-02-26 2021-11-08 바이엘 악티엔게젤샤프트 해충 방제제로서의 축합된 비시클릭 헤테로시클릭 유도체
EP4240350A4 (fr) * 2020-11-09 2024-09-18 Arena Pharmaceuticals, Inc. <sup2/>? <sub2/>?1?procédés de traitement d'états liés au récepteur s1p
US11932078B2 (en) 2021-03-31 2024-03-19 Tesla, Inc. Electric vehicle heat pump using enhanced valve unit

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444766A (en) * 1980-10-21 1984-04-24 Boehringer Mannheim Gmbh Sulfur-containing phospholipid compounds and therapeutic compositions
JP2579602B2 (ja) * 1992-10-21 1997-02-05 吉富製薬株式会社 ２−アミノ−１，３−プロパンジオール化合物および免疫抑制剤
US5948820A (en) * 1994-08-22 1999-09-07 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and pharmaceutical use thereof
US5447922A (en) * 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
IL155065A (en) * 1997-04-04 2004-01-04 Mitsubishi Pharma Corp History - 2 Aminopropene - 1, 3 - Diol and Pharmaceutical Preparations Containing Them
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
WO2000001388A1 (fr) * 1998-07-02 2000-01-13 Kyowa Hakko Kogyo Co., Ltd. Medicaments antidiabetiques
AU767241B2 (en) * 1998-09-14 2003-11-06 Qiang Xu Immunosuppressive agents
US20020143034A1 (en) * 1998-12-30 2002-10-03 Fujisawa Pharmaceutical Co. Ltd. Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
WO2001098301A1 (fr) 2000-06-20 2001-12-27 Japan Tobacco Inc. Composes de pyrazolopyridine et utilisation de ces derniers en tant que medicaments
PL359411A1 (en) * 2000-07-13 2004-08-23 Sankyo Company, Limited Amino alcohol derivatives
JP2002053575A (ja) 2000-08-09 2002-02-19 Sankyo Co Ltd アミノアルコ−ル類
AU2001285331B2 (en) 2000-08-31 2006-04-06 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
CA2437358A1 (fr) 2001-01-30 2002-08-22 University Of Virginia Patent Foundation Agonistes et antagonistes de recepteurs de sphingosine-1-phosphate
DE60234318D1 (de) * 2001-02-08 2009-12-24 Ono Pharmaceutical Co Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors
DE60213766T2 (de) * 2001-02-22 2007-08-02 Novartis Ag Verwendung von beschleunigten lymphozyten zielansteuernden wirkstoffen zur herstellung eines medikaments für die behandlung der verzögertern transplantat-funktion
ATE314383T1 (de) 2001-03-26 2006-01-15 Novartis Pharma Gmbh 2-amino-propanol derivate
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
DE60230262D1 (de) * 2001-05-10 2009-01-22 Ono Pharmaceutical Co Carbonsäurederivate und diese als wirkstoff enthaltende arzneimittel
JP2004534772A (ja) 2001-05-24 2004-11-18 藤沢薬品工業株式会社 アミノアルコール誘導体
JPWO2003020313A1 (ja) * 2001-09-04 2004-12-16 小野薬品工業株式会社 スフィンゴシン−１−リン酸受容体調節剤からなる呼吸器疾患治療剤
US6963012B2 (en) * 2001-09-27 2005-11-08 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
PT1431284E (pt) 2001-09-27 2008-01-21 Kyorin Seiyaku Kk Derivado de sulfureto de diarilo, um seu sal de adição e imunossupressor
JP4035759B2 (ja) 2001-11-06 2008-01-23 独立行政法人産業技術総合研究所 アミノアルコールリン酸化合物、製造方法、及びその利用方法
JP2005112721A (ja) 2001-11-06 2005-04-28 Maruha Corp 含窒素化合物、製造法、及びその利用方法
WO2003051876A1 (fr) 2001-12-14 2003-06-26 Japan Tobacco Inc. Derives de pyrazolopyridine et son utilisation medicinale
JP4771511B2 (ja) 2003-07-08 2011-09-14 第一三共株式会社 アミノアルコ−ル誘導体又はホスホン酸誘導体を含有する医薬組成物
CA2473461C (fr) * 2002-01-11 2011-11-01 Sankyo Company, Limited Derive d'amino-alcool ou derive d'acide phosphonique et composition medicamenteuse les contenant
JP2003267936A (ja) 2002-01-11 2003-09-25 Sankyo Co Ltd ベンゼン環化合物
ATE448193T1 (de) 2002-01-18 2009-11-15 Merck & Co Inc ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
US20040058894A1 (en) * 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists
CA2472680A1 (fr) 2002-01-18 2003-07-31 Merck & Co., Inc. Antagonistes selectifs du recepteur s1p1/edg1
ATE441654T1 (de) 2002-01-18 2009-09-15 Merck & Co Inc Edg-rezeptoragonisten
EP1482896A4 (fr) * 2002-03-01 2005-11-23 Merck & Co Inc Aminoalkylphosphonates et composes associes utilises en tant qu'agonistes du recepteur edg
WO2003073986A2 (fr) 2002-03-01 2003-09-12 Merck & Co., Inc. Aminoalkylphosphonates et composes associes utilises en tant qu'agonistes du recepteur edg
CA2488117A1 (fr) 2002-06-17 2003-12-24 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates et 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates utilises en tant qu'agonistes du recepteur edg
AU2003248245A1 (en) * 2002-06-26 2004-01-19 Ono Pharmaceutical Co., Ltd. Remedies for diseases caused by vascular contraction or dilation
AU2003259296A1 (en) * 2002-07-30 2004-02-16 University Of Virginia Patent Foundation Compounds active in spinigosine 1-phosphate signaling
AU2003273865A1 (en) 2002-09-13 2004-04-30 Novartis Ag Amino-propanol derivatives
EP1548003A4 (fr) 2002-09-19 2006-06-07 Kyorin Seiyaku Kk Derive d'amino-alcool, sel d'addition de ce dernier et immunosuppresseur
EP2251007A3 (fr) * 2002-09-24 2011-03-23 Novartis AG Agonistes du récepteur de la sphingosine-1-phosphate (S1P) pour son utilisation dans le traitement des maladies démyélinisantes
JP4691988B2 (ja) * 2002-10-03 2011-06-01 小野薬品工業株式会社 Ｌｐａ受容体拮抗剤
JP4140698B2 (ja) 2002-10-18 2008-08-27 第一三共株式会社 リン酸又はホスホン酸誘導体
CA2509218C (fr) 2002-12-20 2010-09-07 Merck & Co., Inc. 1-(amino)indanes et (1,2-dihydro-3-amino)-benzofuranes, benzothiophenes et indoles utilises en tant qu'agonistes du recepteur edg
CA2515638A1 (fr) * 2003-02-11 2004-08-26 Shifeng Pan Nouveaux composes bicycliques et compositions associees
CA2515574C (fr) * 2003-02-18 2012-03-13 Kyorin Pharmaceutical Co., Ltd. Derives d'acide aminophosphonique, leurs sels d'addition et des modulateurs de recepteurs s1p
JP2004307441A (ja) 2003-04-10 2004-11-04 Kyorin Pharmaceut Co Ltd ベンゼン誘導体とその付加塩及び免疫抑制剤
JP2004307439A (ja) 2003-04-10 2004-11-04 Kyorin Pharmaceut Co Ltd アミノジオール誘導体とその付加塩及び免疫抑制剤
JP2004307440A (ja) 2003-04-10 2004-11-04 Kyorin Pharmaceut Co Ltd ２−アミノ‐１，３‐プロパンジオール誘導体とその付加塩
JP2004307442A (ja) 2003-04-10 2004-11-04 Kyorin Pharmaceut Co Ltd ヘテロ環誘導体とその付加塩及び免疫抑制剤
AU2004234067B2 (en) * 2003-04-30 2008-02-28 Novartis Ag Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators
WO2004096752A1 (fr) 2003-04-30 2004-11-11 Novartis Ag Derives d'amino-propanol comme modulateurs de recepteur de sphingosine-1-phosphate
JP2006528980A (ja) * 2003-05-15 2006-12-28 メルク　エンド　カムパニー　インコーポレーテッド Ｓ１ｐ受容体作働薬としての３−（２−アミノ−１−アザシクロ）−５−アリール−１，２，４−オキサジアゾール類
WO2004113330A1 (fr) 2003-05-19 2004-12-29 Irm Llc Compositions et composes immunosuppresseurs
CN1791395B (zh) 2003-05-19 2012-09-26 Irm责任有限公司 免疫抑制剂化合物及组合物
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
GB0313612D0 (en) 2003-06-12 2003-07-16 Novartis Ag Organic compounds
JP2005047899A (ja) 2003-07-11 2005-02-24 Sankyo Co Ltd アミノアルコール化合物
TW200510437A (en) 2003-08-12 2005-03-16 Mitsubishi Pharma Corp Phosphinane compound with immunomodulating activity
WO2005014525A2 (fr) 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Compose bi-aryle presentant une activite immunosuppressive
US7528120B2 (en) * 2003-08-28 2009-05-05 Novartis Ag Aminopropanol derivatives
CN1874991A (zh) * 2003-08-29 2006-12-06 小野药品工业株式会社 能够结合s1p受体的化合物及其药物用途
AU2004277947A1 (en) 2003-10-01 2005-04-14 Merck & Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as S1P receptor agonists
GB0324210D0 (en) 2003-10-15 2003-11-19 Novartis Ag Organic compounds
WO2005041899A2 (fr) 2003-11-03 2005-05-12 University Of Virginia Patent Foundation Agonistes et antagonistes du recepteur de la sphingosine-1-phosphate pouvant etre pris par voie orale
WO2005044780A1 (fr) 2003-11-10 2005-05-19 Kyorin Pharmaceutical Co., Ltd. Derive d'acide aminocarboxylique, son sel d'addition et agent de regulation du recepteur s1p
AU2004299456B2 (en) 2003-12-17 2010-10-07 Merck Sharp & Dohme Corp. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
TW200526548A (en) 2003-12-25 2005-08-16 Sankyo Co Ether derivatives
GB0401332D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
US7718704B2 (en) * 2004-02-24 2010-05-18 Irm Llc Immunosuppressant compounds and compositions
TW200538433A (en) * 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
RU2332212C2 (ru) 2004-02-24 2008-08-27 Санкио Компани, Лимитед Аминоспирт
JP2005247691A (ja) 2004-03-01 2005-09-15 Toa Eiyo Ltd Ｓ１ｐ３受容体拮抗薬
GB0405289D0 (en) 2004-03-09 2004-04-21 Novartis Ag Organic compounds
GB0411929D0 (en) * 2004-05-27 2004-06-30 Novartis Ag Organic compounds
US8039674B2 (en) * 2004-06-23 2011-10-18 Ono Pharmaceutical Co., Ltd. Compound having S1P receptor binding potency and use thereof
PL1772145T3 (pl) * 2004-07-16 2011-08-31 Kyorin Seiyaku Kk Sposób skutecznego stosowania leku i sposób dotyczący zapobiegania efektom ubocznym
TW200611687A (en) * 2004-07-29 2006-04-16 Sankyo Co Pharmaceutical compositions used for immunosuppressant
BRPI0514316A (pt) 2004-08-13 2008-06-10 Praecis Pharm Inc métodos e composições para modulação de atividade de receptor de esfingosina-1-fosfato (s1p)
JPWO2006041015A1 (ja) * 2004-10-12 2008-05-15 杏林製薬株式会社 アミノアルコール誘導体とその付加塩及び免疫抑制剤
RU2376285C2 (ru) * 2004-10-12 2009-12-20 Киорин Фармасьютикал Ко., Лтд. Процесс получения гидрохлорида 2-амино-2-[2-[4-(3-бензилоксифенилтио)-2-хлорфенилэтил]-1,3-пропандиола] и его гидратов, а также промежуточные продукты их получения
JP2008522977A (ja) 2004-12-06 2008-07-03 ユニバーシティ オブ バージニア パテント ファンデーション スフィンゴシン＝１−リン酸のアリールアミドアナログ
TW200702326A (en) 2005-05-31 2007-01-16 Mitsubishi Pharma Corp 2-aminobutanol compound and its pharmaceutical use
TWI418350B (zh) * 2005-06-24 2013-12-11 Sankyo Co 含有ｐｐａｒ調節劑之醫藥組成物的用途
SG165364A1 (en) * 2005-09-09 2010-10-28 Novartis Ag Treatment of autoimmune diseases
DK1932522T3 (da) 2005-10-07 2012-07-02 Kyorin Seiyaku Kk Terapeutisk middel mod leversygdom indeholdende 2-amino-1,3-propandiolderivat som aktiv bestanddel
EP1935874A4 (fr) 2005-10-12 2010-10-13 Toa Eiyo Ltd Antagoniste du récepteur de s1p3
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
EP2017257B1 (fr) 2006-04-28 2014-08-06 Mitsubishi Tanabe Pharma Corporation Compose 2-aminobutanol et son utilisation a but medical
US20080025973A1 (en) * 2006-07-25 2008-01-31 Alcon Manufacturing, Ltd. Antagonists of endothelial differentiation gene subfamily 3 (edg-3, s1p3) receptors for prevention and treatment of ocular disorders
US7877152B2 (en) * 2006-07-31 2011-01-25 JusJas LLC Bipolar stimulation/recording device with widely spaced electrodes

Also Published As

Publication number Publication date
US20090325907A1 (en) 2009-12-31
WO2008018427A1 (fr) 2008-02-14
HK1131154A1 (en) 2010-01-15
CY1114681T1 (el) 2016-10-05
EP2058317A4 (fr) 2011-06-29
SG174028A1 (en) 2011-09-29
PT2058317E (pt) 2013-12-11
AU2007282536A1 (en) 2008-02-14
US8232319B2 (en) 2012-07-31
RU2009106934A (ru) 2010-09-20
SI2058317T1 (sl) 2014-01-31
KR101339976B1 (ko) 2013-12-10
ES2438265T3 (es) 2014-01-16
MY152176A (en) 2014-08-15
MA30663B1 (fr) 2009-08-03
DK2058317T3 (da) 2014-01-06
ME02095B (fr) 2014-06-30
RS53080B (sr) 2014-06-30
EP2058317B1 (fr) 2013-10-16
JP5188972B2 (ja) 2013-04-24
MX2009001456A (es) 2009-02-19
HRP20131172T1 (hr) 2014-01-17
CN101501049B (zh) 2013-04-24
NZ574011A (en) 2011-10-28
ZA200900206B (en) 2009-12-30
IL196275A0 (en) 2009-09-22
IL196275A (en) 2013-10-31
KR20090046929A (ko) 2009-05-11
JPWO2008018427A1 (ja) 2009-12-24
EP2058317A1 (fr) 2009-05-13
TNSN08545A1 (en) 2010-04-14
CN101501049A (zh) 2009-08-05
PL2058317T3 (pl) 2014-03-31
CA2659598A1 (fr) 2008-02-14
RU2430925C2 (ru) 2011-10-10

Similar Documents

Publication Publication Date Title
NO20090606L (no) Aminofosforsyreester derivat og S1P reseptor modulator inneholdende den samme som aktiv ingresiens
MA32150B1 (fr) Inhibiteurs heterocycliques de la stearoyl-coa desaturase
EP2172472A3 (fr) Dérivés d&#39;acides aminophosphoniques et leurs sels d&#39;addition en tant que modulateurs du récepteur S1P
BR112013006531A2 (pt) composições fungicidas
MY159358A (en) Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
NO20091620L (no) Boronsyre og estere som inhibitorer av fettsyreamidhydrolaser
EP2613782A4 (fr) Dérivés d&#39;indazole utilisables en tant qu&#39;inhibiteurs de la voie erk
WO2009155121A3 (fr) Inhibiteurs de la pi3 kinase
NO20030398L (no) Estere av 5-aminolevulinsyre som fotosensibiliserende midler i fotokjemoterapi
WO2010065579A3 (fr) Composés hétérocycliques fongicides
NO20092587L (no) LXR og FXR modulatorer
EA201000805A1 (ru) Бис-(сульфониламино)производные в терапии 066
NO20083220L (no) Heterocykliske derivater som modulatorer for ionekanaler
NO20083267L (no) Azaindole inhibitorer av aurora kinaser
BR112012028857A2 (pt) formulações farmacêuticas que compreendem derivados de 1-(beta-d-glucopiranosil)-2-tienil-metilbenzeno como inibidores de sglt
CO6351685A2 (es) Metodo para controlar vegetacion mimosoideae no deseada
WO2008132600A3 (fr) Antagonistes de trpv1 et utilisations de ceux-ci
WO2009035997A3 (fr) Hétérocycles benzo-fusionnés
UA95481C2 (ru) Производные тетразола, фунгицидная композиция на их основе, применение их для радикальной или предупредительной борьбы с фитопатогенными грибами растений или злаковых культур и способ борьбы с фитопатогенными грибами
NO20071117L (no) Substituerte propenyl-piperazinderivater som nye inhibitorer av histondeacetylase
WO2009077559A3 (fr) Dérivés de 5-oxo-3-pyrrolidinecarboxamide utilisés comme modulateurs de p2x7
UA94468C2 (ru) Производные тетразола, фунгицидная композиция на их основе, применение их для радикальной или предупредительной борьбы с фитопатогенными грибами растений или злаковых культур и способ борьбы с фитопатогенными грибами
MX2009010302A (es) Derivados de indol que tienen actividad inhibidora de cpla2 y aplicaciones y metodos de produccion.
NO20073170L (no) Kaspaseinhibitorer og anvendelse derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application